Holen Sie sich die Stockscreener-App
90.31
0.83%
0.74
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$89.57
Offen:
$90
24-Stunden-Volumen:
1.35M
Relative Volume:
1.26
Marktkapitalisierung:
$44.67B
Einnahmen:
$9.76B
Nettoeinkommen (Verlust:
$1.16B
KGV:
38.59
EPS:
2.34
Netto-Cashflow:
$665.00M
1W Leistung:
+0.29%
1M Leistung:
+2.00%
6M Leistung:
-4.56%
1J Leistung:
+13.20%
1-Tages-Spanne:
$89.65
$90.68
1-Wochen-Bereich:
$88.56
$90.68
52-Wochen-Spanne:
$77.54
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
90.31 | 44.67B | 9.76B | 1.16B | 665.00M | 2.34 |
|
ISRG
Intuitive Surgical Inc
|
591.79 | 211.07B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.43 | 65.30B | 20.64B | 1.73B | 2.94B | 6.02 |
|
RMD
Resmed Inc
|
231.69 | 34.04B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
88.48 | 17.62B | 3.90B | 392.30M | 288.10M | 1.95 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Alcon Hit With Suit Over Allegedly Contaminated Eye Drops - Law360
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings - MSN
Alcon launches Voyager laser trabeculoplasty platform in US - Optics.org
Alcon Releases Voyager DSLT for Glaucoma & Ocular Hypertension in U.S. - MPO-mag
Alcon to Roll Out New Glaucoma, Ocular Hypertension Laser Therapy in US -February 19, 2025 at 09:17 am EST - Marketscreener.com
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension - Business Wire
Alcon Inc.'s (VTX:ALC) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat? - Simply Wall St
Growth Report 2: Alcon Mechanical Plans Tech Investments - businessjournaldaily.com
Judge Finds No Infringement In Alcon's Eye Drop Patent Suit - Law360
Alcon Fights for Veto Rights in Aurion's Planned Public Offering - Bloomberg Law
Alcon Loses Patent Ruling on Padagis Copy of Simbrinza Eye Drops - Bloomberg Law
Alcon: T. Rowe Price above 3% of voting rights -February 10, 2025 at 10:40 am EST - Marketscreener.com
Tesla, Musk, Warner Bros. Ask To Toss 'Blade Runner' AI Suit - Law360
Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation - Seeking Alpha
Alcon Laboratories is considering a major $100M expansion of its Fort Worth campus - AOL
Alcon Loses Bid to Veto Aurion IPO, Can Still Oppose Listing (1) - Bloomberg Law
Intraocular Lens Market Forecast and Company Analysis Report 2025-2033 Featuring Alcon, Bausch Health, Hoya, Johnson & Johnson, STAAR Surgical Co, Carl Zeiss Meditec, and Novartis - GlobeNewswire
Alcon stock price target cut to $106 by Needham, maintains Buy - MSN
Alcon Breaks Above 200-Day Moving AverageBullish for ALC - Nasdaq
Artificial Tears Market Overall Study Report 2025-2032 | - openPR
Alcon stock price target cut to $105 by KeyBanc - MSN
Apple To $253? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Do Options Traders Know Something About Alcon (ALC) Stock We Don't? - Yahoo Finance
First Week of March 21st Options Trading For Alcon (ALC) - Nasdaq
Alcon Inc (ALC) Shares Up 3.7% on Jan 21 - GuruFocus.com
Modernizing a Legacy Application on AWS Serverless with Alcon - AWS Blog
Modernizing a Legacy Application on AWS Serverless with Alcon | Case Study | AWS - AWS Blog
Alcon to Seek M&A -January 14, 2025 at 07:30 pm EST - Marketscreener.com
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Yahoo Finance
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Redburn raises Alcon stock rating to Buy By Investing.com - Investing.com Nigeria
Redburn raises Alcon stock rating to Buy - Investing.com
Dry Eye Disease Market Is Booming Worldwide 2025-2032 | Novartis - openPR
Contact Lens Market Deep Research Report with Forecast by 2031 | Bausch & Lomb Incorporated, Alcon Vision LLC - EIN News
Alcon Inc. (VTX:ALC) is favoured by institutional owners who hold 63% of the company - Simply Wall St
Seeing Brilliance in APAC: Alcon’s Vision Care Innovations and Eye Health Mission - BSA bureau
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Alcon Laboratories issues recall for Systane eye drops due to fungal contamination - Top Class Actions
News Release – DOH Issues Recall Alert For Alcon Laboratories Systane Brand Lubricant Eye Drops Due to Fungal - EIN News
DOH issues recall alert for Alcon Laboratories Systane Brand Lubricant Eye Drops - Maui Now
Alcon Labs recalling eye drops - Valley News
Alcon Laboratories Recalls Systane Eye Drops Nationwide Over Fungal Contamination Risk - Black Enterprise
Alcon's (VTX:ALC) investors will be pleased with their respectable 41% return over the last five years - Simply Wall St
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):